Progress in Haploidentical Stem Cell Transplantation

Overview

Journal Biol Blood Marrow Transplant

Date 2011 Oct 5

PMID 21835146

Citations 12

Authors

Ulas D Bayraktar

Richard E Champlin

Stefan O Ciurea

Affiliations

Soon will be listed here.

Abstract

Haploidentical stem cell transplantation is an attractive form of transplantation because of the immediate donor availability, ease of stem cell procurement, and the possibility to further collect donor cells for cellular therapy. Historically, maintaining T cells in the graft has been associated with very high rates of graft-versus-host-disease (GVHD), whereas T cell-depleted haploidentical transplantation has been limited by a higher incidence of graft rejection and nonrelapse mortality related to infectious complications as a result of delayed immune reconstitution posttransplantation. Recent approaches have attempted to eliminate the alloreactive T cells to prevent GVHD posttransplantation. Administration of high-dose cyclophosphamide early posttransplantation in combination with tacrolimus and mycophenolate mofetil has produced engraftment and GVHD rates similar to HLA-matched sibling transplants, suggesting that the most important barriers against successful haploidentical transplantation can be overcome. Future directions should focus on optimizing conditioning regimens for different diseases and prevention of disease relapse posttransplantation.

Citing Articles

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.

Al Malki M, Yang D, Labopin M, Afanasyev B, Angelucci E, Bashey A Blood Adv. 2020; 4(9):2073-2083.

PMID: 32396617 PMC: 7218425. DOI: 10.1182/bloodadvances.2020001499.

Is a matched unrelated donor search needed for all allogeneic transplant candidates?.

Ciurea S, Bittencourt M, Milton D, Cao K, Kongtim P, Rondon G Blood Adv. 2018; 2(17):2254-2261.

PMID: 30206098 PMC: 6134218. DOI: 10.1182/bloodadvances.2018021899.

Immunity to Infections after Haploidentical Hematopoietic Stem Cell Transplantation.

Aversa F, Prezioso L, Manfra I, Galaverna F, Spolzino A, Monti A Mediterr J Hematol Infect Dis. 2016; 8(1):e2016057.

PMID: 27872737 PMC: 5111540. DOI: 10.4084/MJHID.2016.057.

Haploidentical hematopoietic stem cell transplantation in children with high-risk hematologic malignancies: outcomes with two different strategies for GvHD prevention. Ex vivo T-cell depletion and post-transplant cyclophosphamide: 10 years of....

Dufort G, Castillo L, Pisano S, Castiglioni M, Carolina P, Andrea I Bone Marrow Transplant. 2016; 51(10):1354-1360.

PMID: 27272446 DOI: 10.1038/bmt.2016.161.

Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders.

Zahid M, Rizzieri D Adv Hematol. 2016; 2016:1423493.

PMID: 26949395 PMC: 4754478. DOI: 10.1155/2016/1423493.

References

Symons H, Leffell M, Rossiter N, Zahurak M, Jones R, Fuchs E . Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2009; 16(4):533-42. PMC: 2848533. DOI: 10.1016/j.bbmt.2009.11.022. View

Copelan E . Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354(17):1813-26. DOI: 10.1056/NEJMra052638. View

Hale G, Zhang M, Bunjes D, Prentice H, Spence D, Horowitz M . Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 1998; 92(12):4581-90. View

Ash R, Horowitz M, Gale R, van Bekkum D, Casper J, Gordon-Smith E . Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant. 1991; 7(6):443-52. View

Huang X, Liu D, Liu K, Xu L, Chen H, Han W . Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006; 38(4):291-7. DOI: 10.1038/sj.bmt.1705445. View

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M . Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995; 155(3):1151-64. View

Martin P, Hansen J, Buckner C, Sanders J, Deeg H, Stewart P . Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985; 66(3):664-72. View

Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H . Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998; 339(17):1177-85. DOI: 10.1056/NEJM199810223391701. View

Prentice H, Blacklock H, Janossy G, Gilmore M, Tidman N, Trejdosiewicz L . Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet. 1984; 1(8375):472-6. DOI: 10.1016/s0140-6736(84)92848-4. View

10.

Shier L, Schultz K, Imren S, Regan J, Issekutz A, Sadek I . Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors. Biol Blood Marrow Transplant. 2004; 10(9):624-34. DOI: 10.1016/j.bbmt.2004.05.009. View

11.

Reisner Y, Itzicovitch L, Meshorer A, Sharon N . Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci U S A. 1978; 75(6):2933-6. PMC: 392680. DOI: 10.1073/pnas.75.6.2933. View

12.

Weisdorf D, Anasetti C, Antin J, Kernan N, Kollman C, Snyder D . Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002; 99(6):1971-7. DOI: 10.1182/blood.v99.6.1971. View

13.

Ciurea S, Mulanovich V, Jiang Y, Bassett R, Rondon G, McMannis J . Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2010; 17(8):1169-75. PMC: 4231815. DOI: 10.1016/j.bbmt.2010.11.020. View

14.

Bennett C, Christie J, Ramsdell F, Brunkow M, Ferguson P, Whitesell L . The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27(1):20-1. DOI: 10.1038/83713. View

15.

Ciurea S, de Lima M, Cano P, Korbling M, Giralt S, Shpall E . High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009; 88(8):1019-24. PMC: 4324621. DOI: 10.1097/TP.0b013e3181b9d710. View

16.

Young J, Papadopoulos E, Cunningham I, Castro-Malaspina H, Flomenberg N, Carabasi M . T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood. 1992; 79(12):3380-7. View

17.

Kiehl M, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N . Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004; 22(14):2816-25. DOI: 10.1200/JCO.2004.07.130. View

18.

Kasamon Y, Luznik L, Leffell M, Kowalski J, Tsai H, Bolanos-Meade J . Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2009; 16(4):482-9. PMC: 2998606. DOI: 10.1016/j.bbmt.2009.11.011. View

19.

Perez-Simon J, Kottaridis P, Martino R, Craddock C, Caballero D, Chopra R . Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002; 100(9):3121-7. DOI: 10.1182/blood-2002-03-0701. View

20.

Passweg J, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T . Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004; 18(11):1835-8. DOI: 10.1038/sj.leu.2403524. View